Sep 22, 2020 | News
“The report finds that extending patents on just those five drugs [Prilosec, TriCor, Suboxone, Doryx, and Namenda] will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”
Sep 17, 2020 | Op-Eds
We recently had the honor of testifying before the House Ways and Means Committee on the effects of inaction on coronavirus fiscal legislation. One of us was invited by the Republicans and the other by the Democrats. The basis of the hearing was the Heroes Act, a $3 trillion bill that passed the House in the spring on a party line vote with about $1 trillion in tax cuts and $2 trillion in new spending.
Sep 15, 2020 | News
“An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.”
Sep 14, 2020 | Press Releases
Report details five instances of product hopping that collectively cost $4.7 billion annually.
Sep 11, 2020 | News
“But Alex Brill of the right-leaning American Enterprise Institute said Congress shouldn’t approve more costly economic recovery payments because they aren’t well targeted toward households directly impacted by the pandemic.”